Viracta Therapeutics, Inc. Nasdaq
Equities
US92765F1084
Biotechnology & Medical Research
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
0.733 USD | -96.06% | 0.00% | 0.00% |
05-14 | Viracta Therapeutics Appoints Michael Faerm CFO | MT |
05-14 | Viracta Therapeutics, Inc. Appoints Michael Faerm as Chief Financial Officer | CI |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe1st Jan change | Capi. | |
---|---|---|
+60.88% | 62.59B | |
-2.21% | 41.18B | |
+44.42% | 40.29B | |
-8.29% | 27.9B | |
+12.76% | 26.21B | |
-21.44% | 19.09B | |
+5.61% | 13.08B | |
+24.52% | 12.26B | |
+27.91% | 12.05B |
- Stock Market
- Equities
- VIRX Stock
- Stock
- News Viracta Therapeutics, Inc.
- Transcript : Sunesis Pharmaceuticals, Inc., Q4 2016 Earnings Call, Mar 09, 2017